statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Minerva Neurosciences, Inc. (NASDAQ:NERV  Get Free Report) was the recipient of a large decrease in short interest in March. As of March 15th, there was short interest totalling 38,300 shares...

Minerva Neurosciences, Inc. (NASDAQ:NERV) Sees Significant Decline in Short Interest

BURLINGTON, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...

Minerva Neurosciences Receives Complete Response Letter from FDA for New Drug Application for Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia

StockNews.com downgraded shares of Minerva Neurosciences (NASDAQ:NERV  Free Report) from a hold rating to a sell rating in a research note published on Friday. Minerva Neurosciences Trading...

Minerva Neurosciences (NASDAQ:NERV) Cut to "Sell" at StockNews.com

BURLINGTON, Mass., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...

Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Business Updates

Minerva Neurosciences: Q4 Earnings Insights

StockNews.com upgraded shares of Minerva Neurosciences (NASDAQ:NERV  Free Report) from a sell rating to a hold rating in a research note released on Monday. Minerva Neurosciences Stock...

Minerva Neurosciences (NASDAQ:NERV) Raised to Hold at StockNews.com

StockNews.com lowered shares of Minerva Neurosciences (NASDAQ:NERV  Free Report) from a hold rating to a sell rating in a research note issued to investors on Friday. Minerva Neurosciences...

Minerva Neurosciences (NASDAQ:NERV) Cut to Sell at StockNews.com

Minerva Neurosciences (NASDAQ:NERV  Get Free Report) was downgraded by equities researchers at StockNews.com from a hold rating to a sell rating in a research...

Minerva Neurosciences (NASDAQ:NERV) Stock Rating Lowered by StockNews.com

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates to treat central nervous system diseases. It develops Roluperidone for the treatment of negative symptoms in patients with schizophrenia and MIN-301 for the treatment of Parkinson’s disease. The company was founded by Rogerio Vivaldi Coelho and Goeffrey Robin Race on April 23, 2007 and is headquartered in Burlington, MA.

Watchers	9,680
52-Wk Low	$2.29
52-Wk High	$13.49

Volume	2,186.00
52-Wk High	$13.49
52-Wk Low	$2.29

Period	Estimated	Reported	Surprise	Result
Q2'24	-$0.97	--	--	N/A
Q1'24	-$1.20	-$1.13	5.83%	BEAT
Q4'23	-$0.88	-$1.19	-35.23%	MISSED
Q3'23	-$0.77	-$1.03	-33.77%	MISSED
Q2'23	-$0.72	-$1.12	-56.13%	MISSED

NERV Minerva Neurosciences Inc

About

Feed

News

Sentiment

Earnings

Fundamentals